A highly anticipated clinical trial combining two immunotherapy drugs failed to delay tumor growth in patients with newly diagnosed lung cancer, sending AstraZeneca sharply lower Thursday.

The negative results from the so-called MYSTIC study are a stinging setback to AstraZeneca’s ambition to leapfrog over its cancer immunotherapy rivals.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I solved the cancer problem years ago. Cancer could be cured and/or prevented
    by combined gene therapy and eye drops with dorzolamide. Other approaches
    with toxic drugs are deliberate fraud or innocent mistakes.
    Michael I. Lerman, M.D., Ph.D.
    Cancer causing Genes Expert,
    Laboratory of Immunobilogy, NCI, USA, 1980-2008,
    Board Member, Affina Biotechnologies, Inc., USA, present
    Email: lermanmi@gmail.com

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy